Shares of Health Care sector company Corcept Therapeutics moved -1.4% today, and are now trading at a price of $55.19. The Mid-Cap stock's daily volume was 88,639 compared to its average volume of 963,032. The S&P 500 index returned a 0.0% performance.
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company is based in Redwood City and has 500 full time employees. Its market capitalization is $5,822,710,272.
4 analysts are following Corcept Therapeutics and have set target prices ranging from $76.0 to $130.0 per share. On average, they have given the company a rating of buy. At today's prices, CORT is trading -44.67% away from its average analyst target price of $99.75 per share.
Over the last year, CORT's share price has increased by 143.1%, which represents a difference of 129.9% when compared to the S&P 500. The stock's 52 week high is $75.0 per share whereas its 52 week low is $20.84. With average free cash flows of $135.89 Million that have been growing at an average rate of 0.3% over the last 5 years, Corcept Therapeutics is in a position to continue its strong stock performance trend.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) |
|---|---|---|---|
| 2023 | 127,039 | 139 | 126,900 |
| 2022 | 120,323 | 413 | 119,910 |
| 2021 | 167,892 | 469 | 167,423 |
| 2020 | 151,970 | 1,238 | 150,732 |
| 2019 | 136,117 | 1,088 | 135,029 |
| 2018 | 115,665 | 298 | 115,367 |
